介入治疗肝硬化门静脉高压症研究进展与挑战*

doi:10.3969/j.issn.1672-5069.2024.05.003

实用肝脏病杂志 ›› 2024, Vol. 27 ›› Issue (5): 650-653.doi: 10.3969/j.issn.1672-5069.2024.05.003

介入治疗肝硬化门静脉高压症研究进展与挑战^*

张志强, 方坚, 李东良

350025 福州市福建医科大学福总临床医学院/联勤保障部队第九○○医院肝胆内科(张志强,李东良);福建中医药大学附属第三人民医院肝胆内科(方坚)

收稿日期:2024-06-05 出版日期:2024-09-10 发布日期:2024-09-09
通讯作者: 李东良,E-mail:dongliangli93@163.com
作者简介:张志强,男,36岁,博士研究生。E-mail:411072716@qq.com
基金资助:
^*福建省社会发展引导项目(编号:2021Y0062)

Strategy and challenges of interventional treatment in patients with liver cirrhosis and portal hypertension

Zhang Zhiqiang, Fang Jian, Li Dongliang

Department of Liver Diseases, 900^th Hospital, Joint Logistics Support Force, Clinical Medical College, Fujian Medical University, Fuzhou 350025, Fujian Province, China

Received:2024-06-05 Online:2024-09-10 Published:2024-09-09

摘要/Abstract

关键词: 肝硬化, 门脉高压症, 介入治疗

Key words: Liver cirrhosis, Portal hypertension, Interventional treatment

张志强, 方坚, 李东良. 介入治疗肝硬化门静脉高压症研究进展与挑战^*[J]. 实用肝脏病杂志, 2024, 27(5): 650-653.

Zhang Zhiqiang, Fang Jian, Li Dongliang. Strategy and challenges of interventional treatment in patients with liver cirrhosis and portal hypertension[J]. Journal of Practical Hepatology, 2024, 27(5): 650-653.

参考文献

[1] Moller S, Bendtsen F. The pathophysiology of arterial vasodilatation and hyperdynamic circulation in cirrhosis. Liver Int. 2018;38(4):570-580.
[2] Rosch J, Hanafee WN, Snow H. Transjugular portal venography and radiologic portacaval shunt: an experimental study. Radiology,1969,92(5):1112-1114.
[3] Palmaz JC, Sibbitt RR, Tio FO, et al. Expandable intraluminal vascular graft: a feasibility study. Surgery, 1986,99(2):199-205.
[4] Richter GM, Noldge G, Roeren T, et al. Historical and conceptional aspects of TIPSS. Radiologe, 1994,34(4):158-163.
[5] Bettinger D, Thimme R, Schultheiss M. Implantation of transjugular intrahepatic portosystemic shunt (TIPS): indication and patient selection. Curr Opin Gastroenterol, 20223,8(3):221-229.
[6] Zheng M, Chen Y, Bai J, et al. Transjugular intrahepatic portosystemic shunt versus endoscopic therapy in the secondary prophylaxis of variceal rebleeding in cirrhotic patients: meta-analysis update. J Clin Gastroenterol, 2008,42(5):507-516.
[7] Boyer TD, Haskal ZJ, American Association for the Study of Liver D. The role of transjugular intrahepatic portosystemic shunt (TIPS) in the management of portal hypertension: update 2009. Hepatology,2010,51(1):306.
[8] Salerno F, Camma C, Enea M, et al. Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data. Gastroenterology, 2007,133(3):825-834.
[9] Bucsics T, Hoffman S, Grunberger J, et al. ePTFE-TIPS vs repetitive LVP plus albumin for the treatment of refractory ascites in patients with cirrhosis. Liver Int,2018,38(6):1036-1044.
[10] Grunwald D, Tapper EB, Jiang ZG, et al. A standardized assessment of functional disability predicts 1-year mortality in patients undergoing transjugular intrahepatic portosystemic shunt for refractory ascites. J Clin Gastroenterol, 2016,50(1):75-79.
[11] Mancuso A. An update on management of Budd-Chiari syndrome. Ann Hepatol, 2014,13(3):323-326.
[12] Raja K, Jacob M, Asthana S. Portal vein thrombosis in cirrhosis. J Clin Exp Hepatol, 2014,4(4):320-331.
[13] European Association for the Study of the Liver. Electronic address eee. EASL Clinical Practice Guidelines: Vascular diseases of the liver. J Hepatol, 2016,64(1):179-202.
[14] Habib A, Desai K, Hickey R, et al. Portal vein recanalization-transjugularintrahepatic portosystemic shunt using the transsplenic approach to achieve transplant candidacy in patients with chronic portal vein thrombosis. J Vasc Interv Radiol, 2015,26(4):499-506.
[15] 李莹, 练晶晶, 罗添成, 等. 预防肝硬化食管静脉曲张再出血的成本效果研究. 中华消化杂志, 2016,36(2): 113-118.
[16] Khalili H, Goldman D, Frischhertz S, et al. Clinical images: transjugular intrahepatic portosystemic shunt reduction for management of recurrent hepatic encephalopathy. Ochsner J, 2017, 17(4): 311-316.
[17] Hausegger KA, Karnel F, Georgieva B, et al. Transjugular intrahepatic portosystemic shunt creation with the Viatorr expanded polytetrafluoroethylene-covered stent-graft. J Vasc Interv Radiol, 2004,15(3):239-248.
[18] Sauerbruch T, Mengel M, Dollinger M, et al. Prevention of rebleeding from esophageal varices in patients with cirrhosis receiving small-diameter stents versus hemodynamically controlled medical therapy. Gastroenterology, 2015,149(3):660-668, e661.
[19] Olson E, Yune HY, Klatte EC. Transrenal-vein reflux ethanol sclerosis of gastroesophageal varices. AJR,1984,143(3):627-628.
[20] Kanagawa H, Mima S, Kouyama H, et al. Treatment of gastric fundal varices by balloon-occluded retrograde transvenous obliteration. J Gastroenterol Hepatol, 1996,11(1):51-58.
[21] Saad WE, Darcy MD. Transjugular intrahepatic portosystemic shunt (TIPS) versus balloon-occluded retrograde transvenous obliteration (BRTO) for the management of gastric varices. Semin Intervent Radiol, 2011,28(3):339-349.
[22] Saad WE. Balloon-occluded retrograde transvenous obliteration of gastric varices: concept, basic techniques, and outcomes. Semin Intervent Radiol, 2012,29(2):118-128.
[23] Takuma Y, Nouso K, Makino Y, et al. Prophylactic balloon-occluded retrograde transvenous obliteration for gastric varices in compensated cirrhosis. Clin Gastroenterol Hepatol, 2005,3(12):1245-1252.
[24] Park JK, Saab S, Kee ST, et al. Balloon-occluded retrograde transvenous obliteration (BRTO) for treatment of gastric varices: Review and Meta-analysis. Dig Dis Sci,2015,60(6):1543-1553.
[25] Saad WE, Sabri SS. Balloon-occluded retrograde transvenous obliteration (BRTO): Technical results and outcomes. Semin Intervent Radiol, 2011,28(3):333-338.
[26] FE M. Embolic therapy of hypersplenism. Invest Radiol, 1973,8:280-281.
[27] Spigos DG, Jonasson O, Mozes M, et al. Partial splenic embolization in the treatment of hypersplenism. AJR , 1979,132(5):777-782.
[28] Bisharat N, Omari H, Lavi I, et al. Risk of infection and death among post-splenectomy patients. J Infect,2001,43(3):182-186.
[29] Holdsworth RJ, Irving AD, Cuschieri A. Postsplenectomy sepsis and its mortality rate: actual versus perceived risks. Br J Surg, 1991,78(9):1031-1038.
[30] Ahuja C, Farsad K, Chadha M. An overview of splenic embolization. AJR, 2015,205(4):720-725.
[31] Sangro B, Bilbao I, Herrero I, et al. Partial splenic embolization for the treatment of hypersplenism in cirrhosis. Hepatology, 1993,18(2):309-314.
[32] Bessoud B, Denys A, Calmes JM, et al. Nonoperative management of traumatic splenic injuries: is there a role for proximal splenic artery embolization? AJR , 2006,186(3):779-785.
[33] Koconis KG, Singh H, Soares G. Partial splenic embolization in the treatment of patients with portal hypertension: a review of the english language literature. J Vasc Interv Radiol, 2007,18(4):463-481.
[34] Moon E, Tam MD, Kikano RN, et al. Prophylactic antibiotic guidelines in modern interventional radiology practice. Semin Intervent Radiol, 2010,27(4):327-337.
[35] 杨卷红,吴博云,李金保,等.急诊PTVE治疗肝硬化并发食管胃底静脉曲张破裂出血.实用肝脏病杂志.2013;16(6): 548-549.

介入治疗肝硬化门静脉高压症研究进展与挑战^*

Strategy and challenges of interventional treatment in patients with liver cirrhosis and portal hypertension

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	韦新焕, 柳雅立, 张晶, 贾继东. 代谢相关性脂肪性肝硬化诊疗进展^*[J]. 实用肝脏病杂志, 2024, 27(5): 641-645.
[2]	信亮亮, 温智. 2D-SWE技术联合FIB-4和血清VEGF水平评估乙型肝炎肝硬化患者食管静脉曲张价值研究^*[J]. 实用肝脏病杂志, 2024, 27(5): 737-740.
[3]	李瑞妮, 王莎莎, 贾泽博, 韦晓洁, 王腾. 聚桂醇和蛇毒血凝酶注射配合内镜下套扎治疗乙型肝炎肝硬化并发EVB患者疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(5): 741-744.
[4]	田琳, 康颖, 崔洁, 石颖鹏. 内镜下套扎联合奥曲肽和凝血酶治疗肝硬化并发食管胃静脉曲张出血患者疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(5): 745-748.
[5]	李双玲, 刘丽, 陈艺, 李坤. 富马酸丙酚替诺福韦与恩替卡韦治疗高血清病毒载量的代偿期乙型肝炎肝硬化患者效果比较研究^*[J]. 实用肝脏病杂志, 2024, 27(5): 749-752.
[6]	连作勤, 王世明, 张甲, 李付平. 富马酸丙酚替诺福韦联合复方鳖甲软肝片治疗乙型肝炎肝硬化患者疗效和安全性评估^*[J]. 实用肝脏病杂志, 2024, 27(5): 753-756.
[7]	昝双江, 于恬, 戴静. 直接抗病毒药物治疗丙型肝炎肝硬化患者血清血小板生成素和外周血血小板计数变化^*[J]. 实用肝脏病杂志, 2024, 27(5): 757-760.
[8]	张怀东, 雷宇, 周智. 失代偿期肝硬化合并肝外脓肿患者临床特点分析[J]. 实用肝脏病杂志, 2024, 27(5): 761-764.
[9]	任浩, 熊清芳. 多种无创检测指标预测自身免疫性肝病患者肝硬化效能比较^*[J]. 实用肝脏病杂志, 2024, 27(4): 535-538.
[10]	赵维波, 王源, 孔令甲, 朱玉森, 岳宗柱, 商西单. 球囊压迫辅助下内镜硬化剂注射治疗乙型肝炎肝硬化并发食管静脉曲张患者疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(4): 559-562.
[11]	邢世磊, 李之慧, 宁秀景. 乙型肝炎肝硬化并发自发性细菌性腹膜炎患者血清MCP-1、TNF-α和IL-10水平变化及其与病情复发的关系研究^*[J]. 实用肝脏病杂志, 2024, 27(4): 563-566.
[12]	艾孜江·艾买提, 阿布都西库尔·阿布都米吉提, 迪丽努尔·阿卜杜热合曼, 吴源泉. 骨髓间充质干细胞移植联合自拟中药治疗失代偿期肝硬化患者效果研究^*[J]. 实用肝脏病杂志, 2024, 27(4): 567-570.
[13]	樊亚楠, 纪童童, 李鑫飞, 于岩岩, 彭虹, 徐小元, 徐京杭. 两中心肝硬化住院患者病因构成和并发症分布研究[J]. 实用肝脏病杂志, 2024, 27(4): 571-574.
[14]	李维新, 索爱军, 王秀峰. 地佐辛联合丙泊酚靶控输注处理接受内镜下注射硬化剂治疗的乙型肝炎肝硬化并发食管静脉曲张破裂出血患者麻醉苏醒和镇痛效果研究^*[J]. 实用肝脏病杂志, 2024, 27(4): 575-578.
[15]	汤泽宇, 顾菲, 周健文, 姜小兰, 毛雨婧, 樊琦. CT参数联合FIB-4和血清VEGF水平预测乙型肝炎肝硬化患者并发食管静脉曲张效能分析^*[J]. 实用肝脏病杂志, 2024, 27(4): 579-582.